β-Blockers and coronary flow reserve: The importance of a vasodilatory action

Drugs

Volumn 68, Issue 5, 2008, Pages 579-550

  Galderisi, Maurizio ^a   D'Errico, Arcangelo ^a  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

Beta adrenergic receptor antagonists, therapeutic use; Coronary artery disease

Indexed keywords

ADENOSINE; AMINOPHYLLINE; AMMONIA N 13; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; DILTIAZEM; DIPYRIDAMOLE; DOBUTAMINE; FLUORODEOXYGLUCOSE F 18; LACIDIPINE; METOPROLOL; NEBIVOLOL; NITRIC OXIDE; PERINDOPRIL; PROPRANOLOL; VERAPAMIL; WATER O 15;

BETA ADRENERGIC RECEPTOR BLOCKING; COLD PRESSOR TEST; CORONARY ARTERY BLOOD FLOW; CORONARY FLOW RESERVE; CORONARY VASCULAR RESISTANCE; DOPPLER ECHOCARDIOGRAPHY; DRUG ACTIVITY; DRUG MECHANISM; FLUSHING; HEADACHE; HUMAN; HYPEREMIA; HYPOTENSION; NOTE; POSITRON EMISSION TOMOGRAPHY; SIDE EFFECT; VASODILATATION;

ANGINA;

EID: 41349109763     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868050-00002     Document Type: Note

References (103)

1. Anversa P, Ricci R, Olivetti G. Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy. J Am Coll Cardiol 1988; 7: 1140-9
2. Muller JM, Davis MJ, Chilian WM. Integrated regulation of pressure and flow in the coronary microcirculation. Cardiovasc Res 1996; 32: 668-78
3. Schrader J. Adenosine: a homeostatic metabolite in cardiac energy metabolism. Circulation 1990; 81: 389-91
4. Di Carli MF, Tobes MC, Mangner T, et al. Effects of cardiac sympathetic innervation on coronary blood flow. N Engl J Med 1997; 336: 1208-15
5. Bassenge E, Heusch G. Endothelial and neuro-hormonal control of coronary blood flow in health and disease. Rev Physiol Biochem Pharmacol 1990; 116: 79-165
6. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 2006; 147 Suppl. 1: S193-201
7. Luscher TF. The endothelium and cardiovascular disease: a complex relation. N Engl J Med 1994; 330: 1081-3
8. Quyyumi AA, Dakak N, Andews NP, et al. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 1995; 92: 320-6
9. Lefroy DC, Crake T, Uren NG, et al. An effect of inhibition of nitric oxide synthesis on epicardial coronary artery calibre and coronary blood flow in humans. Circulation 1993; 88: 43-54
10. Kuga T, Mohri M, Egashira K, et al. Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin converting enzyme. J Am Coll Cardiol 1997; 30: 108-12
11. Feigl EO. Coronary physiology. Physiol Rev 1983; 63: 1-205
12. Coffman JD, Gregg DE. Reactive hyperemia characteristics of the myocardium. Am J Physiol 1960; 199: 1143-9
13. Hoffman JIE. Maximal coronary flow and the concept of coronary flow reserve. Circulation 1984; 70: 153-9
14. Hoffmann JIE. Transmural myocardial perfusion. Progr Cardiovasc Dis 1987; 24: 429-64
15. Gould LK, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis: instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol 1974; 33: 87-94
16. Gould LK, Lipscomb K. Effects of coronary stenosis on coronary flow reserve and resistance. Am J Cardiol 1974; 34: 48-55
17. Marcus ML, Chilian WM, Kanatsuka H, et al. Understanding the coronary circulation through studies at the microvascular level. Circulation 1990; 82: 1-7
18. Strauer BE. The significance of coronary reserve in clinical heart disease. J Am Coll Cardiol 1990; 15: 775-83
19. Kozàkovà M, Galetta F, Gregorini L, et al. Coronary vasodilator capacity and epicardial vessel remodeling in physiological and hypertensive hypertrophy. Hypertension 2000; 36: 343-9
20. Galderisi M, de Simone G, Cicala S, et al. Coronary flow reserve in hypertensive patients with appropriate or inappropriate left ventricular mass. J Hypertens 2003; 21: 2183-8
21. Wilson RF, Laxson DD. Caveat emptor: a clinician's guide to assessing the physiologic significance of arterial stenosis. Cathet Cardiovasc Diagn 1993; 29: 93-8
22. Dimitrow PP, Galderisi M, Rigo F. The non-invasive documentation of coronary macrocirculation impairment: role of transthoracic echocardiography. Cardiovasc Ultrasound 2005; 3: 18
23. Rigo F, Gherardi S, Galderisi M, et al. Coronary flow reserve evaluation in stress-echocardiography laboratory. J Cardiovasc Med 2006; 7: 472-9
24. De Bruyne B, Hersbach F, Pijls NH, et al. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but 'normal' coronary angiography. Circulation 2001; 104: 2401-6
25. Schwartzkopff B, Motz W, Frenzel H, et al. Structural and functional alterations of the intramyocardial coronary arteristudies oles in patients with arterial hypertension. Circulation 1993; 88: 993-1003
26. Quinones MJ, Pampaloni MH, Schelbert H, et al. Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med 2004; 140: 700-8
27. Srinivasan M, Herrero P, McGill JB, et al. The effects of plasma insulin and glucose on myocardial blood flow in patients with type 1 diabetes mellitus. J Am Coll Cardiol 2005; 46: 42-8
28. Nitenberg A, Foult JM, Antony I, et al. Coronary flow and resistance reserve in patients with chronic aortic regurgitation, angina pectoris and normal coronary arteries. J Am Coll Cardiol 1998; 11: 478-86
29. Krams R, Kofflard MJ, Duncker DJ, et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 1998; 97: 230-3
30. Canetti M, Akhter MW, Lerman A, et al. Evaluation of myocardial blood flow reserve in patients with chronic congestive heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol 2003; 92: 1246-9
31. Vassalli G, Hess OM. Measurement of coronary flow reserve and its role in patient care. Basic Res Cardiol 1998; 93: 339-53
32. Marcus M, Wright C, Doty D, et al. Measurements of coronary velocity and reactive hyperemia in the coronary circulation in humans. Circ Res 1981; 49: 877-91
33. Pijls NH, De Bruyne B, Smith L, et al. Coronary thermodilution to assess flow reserve: validation in humans. Circulation 2002; 105: 2482-6
34. Storto G, Cirillo P, Vicario ML, et al. Estimation of coronary flow reserve by Tc-99m sestamibi imaging in patients with coronary artery disease: comparison with the results of intracoronary Doppler technique. J Nucl Cardiol 2004; 11: 682-8
35. Wisenberg C, Schelbert HR, Hoffman EJ, et al. In vivo quantification of regional myocardial blood flow by positron-emission computed tomography. Circulation 1981; 63: 1248-58
36. Schwaiger M, Hutchins G. Quantification of regional myocardial perfusion by PET: rationale and first clinical results. Eur Heart J 1995; 16 Suppl. J: 84-91
37. Ibrahim T, Nekolla SG, Schreiber K, et al. Assessment of coronary flow reserve: comparison between contrast-enhanced magnetic resonance imaging and positron emission tomography. J Am Coll Cardiol 2002; 39: 864-70
38. Rimoldi O, Camici PG. PET measurement of the coronary flow reserve and microcirculatory function. Hertz 1999; 24: 522-30
39. Iliceto S, Marangelli V, Memmola C, et al. Transesophageal Doppler echocardiography evaluation of coronary blood flow velocity in baseline condition and during dipyridamole-induced coronary vasodilation. Circulation 1991; 83: 61-9
40. Hozumi T, Yoshida K, Ogata Y, et al. Noninvasive assessment of significant left anterior descending coronary artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography. Circulation 1998; 97: 1557-62
41. Caiati C, Montaldo C, Zedda N, et al. New noninvasive method for coronary flow reserve assessment: contrast enhanced transthoracic second harmonic echo-Doppler. Circulation 1999; 99: 771-8
42. Voci P, Testa G, Plaustro G. Imaging of the distal left anterior descending coronary artery by transthoracic color Doppler echocardiography. Am J Cardiol 1998; 81: 74-8G
43. Sudhir K, MacGregor JS, Barbant SD, et al. Assessment of coronary conductance and resistance vessel reactivity in response to nitroglycerin, ergonovine and adenosine: in vivo studies with simultaneous intravascular two-dimensional and Doppler ultrasound. J Am Coll Cardiol 1993; 21: 1261-8
44. Wilson RF, White CW. Intracoronary papaverine: an ideal coronary vasodilation for studies of the coronary circulation in conscious humans. Circulation 1986; 73: 444-51
45. Christensen CW, Rosen LB, Gal RA, et al. Coronary vasodilator reserve: comparison of the effects of papaverine and adenosine on coronary flow, ventricular function, and myocardial metabolism. Circulation 1991; 83: 294-303
46. Rossen JD, Quillen JE, Lopez AG, et al. Comparison of coronary vasodilation with intravenous dipyridamole and adenosine. J Am Coll Cardiol 1991; 18: 485-91
47. Felder L, Vassalli G, Vassalli F, et al. Clinical significance of coronary flow reserve: effects of papaverine and exercise. Coron Artery Dis 1994; 5: 347-58
48. Voudris V, Manginas A, Vassilikos V, et al. Coronary flow velocity changes after intravenous dipyridamole infusion: measurements using intravascular Doppler guide wire. A documentation of flow inhomogeneity. J Am Coll Cardiol 1996; 27: 1148-55
49. Galderisi M, de Simone G, Cicala S, et al. Coronary flow reserve in hypertensive patients with appropriate or inappropriate left ventricular mass. J Hypertens 2003; 21: 2183-8
50. Takeuchi M, Miyazaki C, Yoshitani H, et al. Assessment of coronary flow velocity with transthoracic Doppler echocardiography during dobutamine stress echocardiography. J Am Coll Cardiol 2001; 38: 117-23
51. Lim HE, Shim WJ, Rhee H, et al. Assessment of coronary flow reserve with transthoracic Doppler echocardiography: comparison among adenosine, standard-dose dipyridamole, and high-dose dipyridamole. J Am Soc Echocardiogr 2000; 13: 264-70
52. Rigo F, Cortigiani L, Pasanisi E, et al. The additional prognostic value of coronary flow reserve on left anterior descending artery in patients with negative stress echo by wall motion criteria: a transthoracic vasodilator stress echocardiography study. Am Heart J 2006; 151: 124-30
53. Rigo F, Gherardi S, Galderisi M, et al. The independent prognostic value of contractile and coronary flow reserve determined by dipyridamole stress echocardiography in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2007; 99: 1154-8
54. Drexler H, Zeiber AM, Wollschlager H, et al. Flow dependent coronary artery dilation in humans. Circulation 1989; 80: 466-74
55. Nabel EG, Ganz P, Gordon JB, et al. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressure test. Circulation 1988; 77: 43-52
56. Zeiher AM, Drexler H, Wollschlaeger H, et al. Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. J Am Coll Cardiol 1989; 14: 1181-90
57. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term out-come of coronary heart disease. Circulation 2000; 101: 1899-906
58. Schwartzkopff B, Brehm M, Mundhenke M, et al. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 2000; 36: 220-5
59. Motz W, Strauer BE. Improvement of coronary flow reserve after long-term therapy with enalapril. Hypertension 1996; 27: 1031-8
60. Vogt M, Strauer BE. Response of hypertensive left ventricular hypertrophy and coronary microvascular disease to calcium antagonists. Am J Cardiol 1995; 76: 24-30D
61. Parodi O, Neglia D, Sambuceti G, et al. Regional myocardial blood flow and coronary reserve in hypertensive patients: the effect of therapy. Drugs 1992; 44 Suppl. 1: 48-55
62. Kuschnir E. Impact of calcium antagonists on the cardiovascular system: experience with lacidipine. Drugs 1999; 57 Suppl. 1: 11-7
63. Tomás JP, Moya JL, Barrios V, et al. Effect of candesartan on coronary flow reserve in patients with systemic hypertension. J Hypertens 2006; 24: 2109-14
64. Akinboboye OO, Chou RL, Bergmann SR. Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan. J Am Coll Cardiol 2002; 40: 703-9
65. Strauer BE, Schwartzkopff B, Kelm M. Assessing the coronary circulation in hypertension. J Hypertens 1998; 16: 1221-33
66. Young MA, Vatner SE, Vatner SF. Alpa- and beta-adrenergic control of large coronary arteries in conscious dogs. Circ Res 1974; 34: 812-23
67. Marshall RJ, Parratt JR. Comparative effects of propranolol and practolol in the early stages of experimental canine myocardial infarction. Br J Pharmacol 1976; 57: 295-303
68. Lichtlen PR, Rafflenbeul W, Jost S, et al. Coronary vasomotion tone in large epicardial coronary arteries with special emphasis on beta-adrenergic vasomotion, effect of beta-blockade. Basic Res Cardiol 1990; 85 Suppl. 1: 335-46
69. Billinger M, Seller C, Fleisch M, et al. Effect of beta-adrenergic blocking agents increase coronary flow reserve? J Am Coll Cardiol 2001; 38: 1866-71
70. Boettcher M, Czernin J, Sun K, et al. Effects of β1 adrenergic blockade on myocardial blood flow and vasodilatory capacity. J Nucl Med 1997; 38: 442-6
71. Gullu H, Erdogan D, Caliskan M, et al. Different effects of atenolol and nebivolol on coronary flow reserve. Heart 2006; 92: 1690-1
72. Strauer BE. The hypertensive heart: effect of atenolol on the function, coronary hemodynamics and oxygen uptake of the left ventricle. Dtsch Med Wochenschr 1978; 103: 1785-9
73. Kern MJ, Ganz P, Horowitz DJ, et al. Potentiation of coronary vasoconstriction by beta-adrenergic blockade in patients with coronary artery disease. Circulation 1983; 67: 1178-85
74. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-90
75. Packer M, Coats AJ, Fowler MB, et al., on behalf of the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8
76. Poole-Wilson PA, Swedberg K, Cleland JG, et al., on behalf of the Carvedilol or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13
77. Flather MD, Shibata MC, Coats AJ, et al., on behalf of the SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-25
78. Koepfli P, Wyss CA, Namdar M, et al. β-Adrenergic blockade and myocardial perfusion in coronary artery disease: differential effects in stenotic versus remote myocardial segments. J Nucl Med 2004; 45: 1628-31
79. Sugioka K, Hozumi T, Takemoto Y, et al. Early recovery of impaired coronary flow reserve by carvedilol therapy in patients with idiopathic dilated cardiomyopathy: a serial transthoracic Doppler echocardiographic study. J Am Coll Cardiol 2005; 45: 318-9
80. Neglia D, De Maria R, Masi S, et al. Effects of long-term treatment with carvedilol on myocardial blood flow in idiopathic dilated cardiomyopathy. Heart 2007; 93: 803-13
81. Sugioka K, Hozumi T, Takemoto Y, et al. Relation of early improvement in coronary flow reserve to late recovery of left ventricular function after beta-blocker therapy in patients with idiopathic dilated cardiomyopathy. Am Heart J 2007; 153: 1080e1-6
82. Galderisi M, Cicala S, D'Errico A, et al. Nebivolol improves coronary flow reserve in hypertensive patients without coronary heart disease. J Hypertens 2004; 22: 2201-8
83. Erdogan D, Gullu H, Caliskan M, et al. Nebivolol improves coronary flow reserve in patients with idiopathic dilated cardiomyopathy. Heart 2007; 93: 319-24
84. Togni M, Vigorito F, Windecker S, et al. Does the beta-blocker nebivolol increase coronary flow reserve? Cardiovasc Drug Ther 2007; 21 (2): 99-108
85. Lorenzoni R, Rosen SD, Camici PG. Effect of alpha1-adrenoceptor blockade on resting and hyperemic myocardial blood flow in normal humans. Am J Physiol 1996; 271: H1302-6
86. Yue TL, Ruffolo Jr RR, Feuerstein G. Antioxidant action of carvedilol: a potential role in treatment of heart failure. Heart Fail Rev 1999; 4: 39-51
87. Kuo L, Davis MJ, Chilian WH. Endothelium-dependent, flow induced dilation of isolated coronary arterioles. Am J Physiol 1990; 259: H1063-70
88. Ignarro LJ, Byrns RE, Trinh K, et al. Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide 2002; 7: 75-82
89. Brehm BR, Bertsch D, von Fallois J, et al. Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2000; 36: S401-3
90. Mundhenke M, Schwartzkopff B, Köstering M, et al. Endogenous plasma endothelin concentrations and coronary circulation in patients with mild dilated cardiomyopathy. Heart 1999; 81: 278-84
91. Lekakis JP, Protogerou A, Papamichael C, et al. Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease. Cardiovasc Drugs Ther 2005; 19: 277-81
92. Corretti MC, Anderson TJ, Benjamin EJ, et al. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65
93. Zeiher AM, Krause T, Schächinger V, et al. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation 1995; 91: 2345-52
94. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995; 25: 1225-31
95. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-80
96. Di Lenarda A, Sabbadini G, Salvatore L, et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol: the Heart-Muscle Disease Study Group. J Am Coll Cardiol 1999; 33: 1926-34
97. Palazzuoli A, Quatrini I, Vecchiato L, et al. Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failure. J Cardiovasc Pharmacol 2005; 45: 563-8
98. Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993; 21: 1094-100
99. Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension: a prospective, randomized, comparison of the long-term effects of atenolol vs nebivolol. Eur J Heart Fail 2003; 5: 621-7
100. Edes I, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail 2005; 7: 631-9
101. Ghio S, Magrini G, Serio A, et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 2006; 27: 506-7
102. Galderisi M, de Simone G, D'Errico A, et al. Three-month nebivolol therapy induces improvement of both left ventricular filling pressure and coronary flow reserve in hypertensive patients without coronary artery disease [abstract]. Eur J Echocardiogr 2006; 7 Suppl. 1: S185
103. Cortigiani L, Rigo F, Gherardi S, et al. Additional prognostic value of coronary flow reserve in diabetic and non diabetic patients with negative dipyridamole stress echocardiography by wall motion criteria. J Am Coll Cardiol 2007; 50: 1354-61